While its net profit, revenue and earnings before interest and tax depreciation and amortization (EBITDA) have increased, its margins have contracted.
Rossari Biotech’s net profit rose 3.2 per cent to ₹32.7 crore from ₹31.7 crore in the previous year.
Its revenue saw an increase of 13.4 per cent to ₹581.6 crore from ₹512.7 crore in the third quarter of the previous fiscal.
The company’s EBITDA also grew 6.3% annually from ₹64.7 crore to ₹68.8 crore.
However, its margin contracted to 11.8%, compared to 12.6% a year earlier.
Shares of Rossari Biotech ended the previous session down almost 1% at ₹534.5 apiece. The stock is down 33.6% over the past year.
Also Read: Punjab and Sind Bank Q3 Results | Profit increases by 19% year-on-year, asset quality improves
John Harbaugh agreed Saturday to become coach of the New York Giants, finalizing the longtime big-market franchise's all-out search for…
Virginia Gov. Abigail Spanberger (D) moved quickly to change direction at the state's universities in her first hours in office…
Lamar Odom faces new legal problems. The two-time NBA champion was arrested and convicted of driving under the influence on…
Polling for the Maharashtra municipal corporation elections, including that of the crucial and cash-rich Brihanmumbai Municipal Corporation (BMC), will be…
Trump appears to rule out Hassett as Fed chairman in his comments.Trump said Hassett was good on television today and…
An incredibly costly fumble by Josh Allen changed the game just before halftime today in Denver.After the Broncos scored a…